Article >> C&EN Nov 13, 2017 > Interview with Dr. Michael Quirmbach at CPhI 2017

Dec 08, 2017
Dr. Michael Quirmbach comments on CordenPharma's recent acquisiton of CordenPharma Boulder in an interview with C&EN at CPhI 2017 entitled > Growth strategies for pharmaceutical chemical makers on display at CPhI.

CordenPharma also arrived at CPhI soon after making an acquisition—in its case a former Hospira plant in Boulder, Colo., that specializes in high-potency APIs, mainly for oncology. Dr. Michael Quirmbach, CordenPharma’s vice president of marketing and sales, said the facility is another in an array of assets for customers developing cancer drugs.
CordenPharma was created by its owner, International Chemical Investors Group, to acquire facilities no longer needed by the drug companies that built them. One of those facilities was a Roche plant, also in Boulder, that specializes in peptide and high-potency APIs. Other CordenPharma sites, such as a former AstraZeneca plant in Plankstadt, Germany, turn APIs for oncology and other markets into finished drug products.
Quirmbach said CordenPharma has sewn its various facilities together to provide a one-stop shop like the one Lonza is striving for. For example, he said, the firm can manufacture oligonucleotides in Boulder; conjugate them in Boulder or Switzerland to N-acetylgalactosamine, an amino sugar that facilitates protein drug delivery; and create a final drug product in Italy.

Real the Full Article Here